These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6859154)

  • 21. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progestogens and arterial disease--evidence from the Royal College of General Practitioners' study.
    Kay CR
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):762-5. PubMed ID: 6801981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma lipoprotein changes during oral contraception.
    Briggs MH; Briggs M
    Curr Med Res Opin; 1979; 6(4):249-54. PubMed ID: 527349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The varying effects of progestins on lipid levels and cardiovascular disease.
    La Rosa JC
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1621-9. PubMed ID: 3132043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: differential changes in high-density lipoprotein subclasses.
    Krauss RM; Roy S; Mishell DR; Casagrande J; Pike MC
    Am J Obstet Gynecol; 1983 Feb; 145(4):446-52. PubMed ID: 6401927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of norethisterone and levonorgestrel in low-dose multiphasic oral contraceptives on serum lipids.
    Wiik P; Nordby J; Paulsen JE
    Acta Obstet Gynecol Scand; 1993 Oct; 72(7):550-5. PubMed ID: 8213103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of oral contraceptives on lipoprotein triglyceride and cholesterol: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):725-31. PubMed ID: 7065054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of oral contraceptive steroids on serum lipids.
    De Alvarez RR; Jahed FM; Spitalny KJ; Elkin H; Jaunakais I
    Am J Obstet Gynecol; 1973 Jul; 116(5):727-49. PubMed ID: 4351501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of contraceptive steroids on hypothalamic-pituitary function.
    Mishell DR; Kletzky OA; Brenner PF; Roy S; Nicoloff J
    Am J Obstet Gynecol; 1977 May; 128(1):60-74. PubMed ID: 403765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral contraceptives.
    Maclennan AH
    Curr Ther (Seaforth); 1987 Dec; 28(12):113-22. PubMed ID: 12317413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy.
    Hirvonen E; Mälkönen M; Manninen V
    N Engl J Med; 1981 Mar; 304(10):560-3. PubMed ID: 7453723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Letter: The effect of contraceptive steroids on carbohydrate metabolism.
    Davidson MB
    Metabolism; 1974 Jul; 23(7):687-90. PubMed ID: 4834911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical and biological justifications for the use of Triella].
    McGuire JL; Pasquale SA; Castaigne JP
    Rev Fr Gynecol Obstet; 1986 Dec; 81(12):731-6. PubMed ID: 3823727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Anovlar in gynaecological disorders and contraception.
    Shahani SM; Chiklikar A
    J Obstet Gynaecol India; 1968 Apr; 18(2):592-7. PubMed ID: 12331827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Problems in evaluating chronic toxicity of contraceptive steroids in dogs.
    Weikel JH; Nelson LW
    J Toxicol Environ Health; 1977 Sep; 3(1-2):167-77. PubMed ID: 72828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral contraceptives and plasma lipids.
    Dhillon MK; Sarkar AK; Gupta AN; Devi PK
    J Obstet Gynaecol India; 1972; 22(6):622-6. PubMed ID: 12332899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.